Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AARDVARC: Imaradenant Combinations in mCRPC
NCT04495179Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of imaradenant in metastatic castration-resistant prostate cancer (mCRPC), sponsored by AstraZeneca. Started Aug 2020; status: completed.
02
Drugs
imaradenant
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04495179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495179.